IIT Delhi researchers design new strategy for developing drug molecules
Abhiraj P | February 18, 2022 | 07:44 PM IST | 1 min read
IIT Delhi researchers claim that the new drug strategy can also help in treating retroviral infections
A complete guide to IITs: Learn about the admission process, required cutoffs, fees, top branches, campus details, and updated placement statistics—all in one place.
Download NowNEW DELHI: A research team from the Indian Institute of Technology (IIT) Delhi has developed a new drug designing strategy to develop potential drug molecules to treat different diseases.
Must See: IITs Comprehensive Guide
The present strategy of using computer-aided rational drug discovery is time-consuming, claims IIT Delhi. The researchers came up with a different approach where the macromolecular interface are mimicked by small molecules. According to the researchers , the new drug strategy can also help in treating retroviral infections.
Also read | IIT Guwahati, South Dakota Mines collaborate for research on 2D materials, biofilms
According to a statement from IIT Delhi, researchers has made use of organic chemistry and biophysics tools to design molecules that target protein interface. The new method is said to make the drug design approach easier compared to the present methods.
The IIT Delhi researcher team was led by V Haridas, professor at the chemistry department of IIT Delhi. Virologist Guruprasad Medigeshi, who is also a professor at the Translational Health Science and Technology Institute (THSTI), and biochemist Bishwajit Kundu, professor at the Kusuma School of Biological Sciences, IIT Delhi accompanied Haridas in the research.
Also read | IIT Madras research can help detect risk of diabetes, other metabolic diseases early
“We used this strategy to design drug molecules, which could be useful for the treatment of Japanese Encephalitis Virus (JEV), the main cause for viral encephalitis in Southeast Asian countries, and protein aggregation diseases such as Alzheimer’s and other related diseases. We have also patented the JEV inhibitor drug molecule,” said Haridas.
Follow us for the latest education news on colleges and universities, admission, courses, exams, research, education policies, study abroad and more..
To get in touch, write to us at news@careers360.com.
Next Story
]Featured News
]- Assam Agricultural University Jorhat enrolled excess students for 5 yrs despite 41% vacant faculty posts: CAG
- AICTE Approval Process Handbook: From 2026-27, more foreign-student seats, minor specialisation in diploma
- 'We refuse to be forgotten’: Students boycott classes at film school govt opened, and then abandoned
- ISB fees high due to quality, 50% students should get some scholarship: Dean
- ‘Teaching through logins’: School teachers waste time on ‘data-entry’ as apps become integral to monitoring
- Not even 30% of central university teachers are women; 25.4% posts vacant: Education ministry data
- Public policy, social impact courses boom despite tepid job scene
- MBA Jobs: Capstone projects, case competitions become key placement tools amid hiring slowdown
- Director General of IMI: ‘MBA courses now need modular curriculum linked to industry problems’
- Goa Institute of Management plans major boost to online courses; ‘AI literacy crucial,’ says director